ReportGem ReportGem

U.S. COMPANY FILING

Moderna, Inc. — Form 10-Q filed 2025-11-06

Filed: 2025-11-06Company: Moderna, Inc.Ticker: MRNAExchange: NasdaqForm: 10-QReport period: 2025-09-30SEC accession: 0001682852-25-000075Event: earningsMateriality: 85

Filing text preview

Moderna reported Q3 2025 net loss of $1.996 billion, EPS -$0.51. Total assets $12.135 billion, cash and investments decreased. R&D expenses reduced by $274 million from Blackstone funding. FDA approved new COVID vaccine mNEXSPIKE, but BARDA contract terminated. Company faces unrealized investment losses and inventory write-downs.

This preview uses text already stored in ReportGem and does not fetch the document from object storage during SEO generation. Review the internal filing record and the official SEC source before relying on it.

Open filing record

Related research and intelligence

Official SEC filing2025-11-06US Treasury to At Least Double Debt Buybacks; Stock Futures Climb2026-08-20Merck and Moderna's Melanoma Vaccine Trial Positive, Vaccine Themed ETFs Surge2026-08-20S&P 500 and Nasdaq Edge Higher, Led by Moderna and Merck2026-08-20US Stock Index Futures Climb As Yields Cool Off Amid Treasury Support2026-08-20Wall St Rises as Yields Ease, Moderna Lifts Healthcare Stocks2026-08-20Moderna Skyrockets 177% on Positive Phase 3 Melanoma Data, Personalized Cancer Vaccine Meets Goal2026-08-2010-Q2026-07-31 · 10-Q